Search results
Results from the WOW.Com Content Network
Another GLP-1 drug, Trulicity, which is also used to treat type 2 diabetes, was its third-best-selling drug, but saw its sales fall 31% to $1.25 billion as patients shifted to its newer GLP-1 ...
From a valuation perspective, Lilly trades at a forward price-to-earnings (P/E) ratio of 37 times 2025 analyst estimates but has a price/earnings-to-growth (PEG) ratio of under 0.4. PEGs below 1 ...
The good news for investors is that for 2025, overall guidance is looking strong. Lilly is projecting between $58 billion and $61 billion in sales, which is mostly higher than the $58.4 billion ...
Amgen's positive trial results update on its GLP-1 injectable for obesity, MariTide, sent its stock up more than 13% in trading Friday.CEO Bob Bradway shared a peek at phase II results of the ...
This page was last edited on 13 September 2017, at 20:21 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
The drugs, known as GLP-1s, have brought in $50 billion in revenue for Novo Nordisk year to date alone, but the high prices ($1,349 for Wegovy and $968 for Ozempic) have put them out of reach for ...
Global Partners LP (NYSE: GLP) is an American energy supply company ranked 361 in the 2018 Fortune 500. [3] The company is organized as a master limited partnership, and its operations focus on the importing of petroleum products and marketing them in North America. It wholesales products like crude oil, diesel oil, gasoline, heating oil and ...
Novo Nordisk CEO Lars Jørgensen isn't too worried about the upcoming Medicare price negotiations over blockbuster GLP-1 drugs, even though the company still stands with the industry against the ...